欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (4): 470-473.

• 研究原著 • 上一篇    下一篇

苯那普利的联合用药选择:左旋氨氯地平与硝本地平缓释片的对比分析

贾鸣, 潘琪宏, 朱梓丰, 黄麟书, 王迎   

  1. 嘉兴医学院附属第二医院心内科, 嘉兴314000, 浙江
  • 收稿日期:2003-08-13 修回日期:2004-02-06 出版日期:2004-04-26 发布日期:2020-11-20
  • 通讯作者: 贾鸣, 男, 副主任医师, 研究方向:心血管疾病诊断与防治。Tel:0573-2031375 E-mail:jxjiaming5@hotmail.com

Selection of combined drugs in patients with hypertension inadequately controlled by benazepril alone:compare the Bp-reducing effects of combination of benazepril and levamlodipine with those of benazepril and nifedepine sustained-release tablet

JIA Ming, PAN Qi-Hong, ZHU Zi-Feng, HUANG Lin-Shu, WANG Ying   

  1. Department of Cardiology, the Second Affiliated Hospital, J iaxing Medical College, Jiaxing 314000, Zhejiang, China
  • Received:2003-08-13 Revised:2004-02-06 Online:2004-04-26 Published:2020-11-20

摘要: 目的:比较苯那普利与苯磺酸左旋氨氯地平和硝本地平缓释片合用, 治疗单用苯那普利不能控制其血压降至目标水平的原发性高血压患者的疗效、副反应。方法:112 例单用苯那普利治疗不能控制至理想血压的患者, 在原有剂量不变下, 加用苯磺酸左旋氨氯地平或硝本地平缓释片治疗, 用药后4周判断降压效果, 不良反应。结果:加用苯磺酸左旋氨氯地平后有效率为85.71 %, 加用硝本地平缓释片为78.57 %, 两组无显著的统计学意义(P >0.05), 加用苯磺酸左旋胺氯地平后的显效率有(73.21 %) 高于加用硝本地平缓释片(54.38 %, P <0.05);不良反应显著低于加用硝本地平组(7.14 %vs 28.5 %, P <0.01) 。结论:对单用苯那普利治疗不能控制其理想血压的患者, 苯那普利合用苯磺酸左旋胺氯地平或苯那普利合用硝本地平缓释片治疗都是有效的。苯那普利和苯磺酸左旋胺氯地平联合更适合于此类病人的抗高血压治疗。

关键词: 原发性高血压, 苯那普利, 苯磺酸左旋氨氯地平, 硝本地平缓释片

Abstract: AIM: To compare the therapy of the combination of benazepril and levamlodipine (B/LA) with benazepriland and nifedepine sustained-release tablet (B/NSr) in patients with mild to moderate hypertension inadequately controlled by benazepril alone.METHODS: Experiments were performed in 112 patients with primary hypertension inadequately controlled by benazepril alone. The patients were randomized divided into two groups. Continued previous benazepril treatment, the B/LA group (n =56) was added levamlodipine, 2.5 mg once daily for 2 weeks, the B/NSr group (n =56) was added nifedepine sustained-release tablets, 10 mg once daily for 2 weeks.Examinations were performed before and at the end of 2 weeks of combination-treatment period.The total combination-treatment period was 4-6 weeks.RESULTS: The overall Bp-reducing efficacious rate of LA/B group was 85.71 %, and that of LA/B group was 78.57 % (P >0.05), but the obvious Bp-reducing rate in B/LA group was 73.21 %, which was significantly higher than that in B/NSr group (57.14 %, P <0.05). The adverse effects rate was 8.93 % in B/LA group and 21.43 % in B/NSr group (P <0.01).CONCLUSION: Either LA/B or B/NSr is effective in the treatment of hypertension inadequately controlled by benazepril alone, but LA/B is more desirable therapy than B/NSr.

Key words: primary hypertension, benazepril, Levamlodipine, nifedepine sustained-release tablet

中图分类号: